AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Sevoflurane [legacy through FY20Q1] by Quarter
Sevoflurane [legacy through FY20Q1] — U.S. net revenues ($M) ($M)
AbbVie Sevoflurane [legacy through FY20Q1]: $16M in Q1 2020, down 5.9% from a year earlier. That is the lowest of the 13 quarters on record here. No newer figure appears in the documents we track.
Where the Q1 2020 figure comes from
Source: Form 10-Q (filed 2020-05-08) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sevoflurane [legacy through FY20Q1] — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2020 | Mar 31, 2020 | 16 | -5.9% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 21 | +5.0% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 18 | 0.0% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 18 | -5.3% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 17 | 0.0% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 20 | -9.1% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 18 | -5.3% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 19 | 0.0% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 17 | -5.6% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 22 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 19 | – | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 19 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 18 | – | Form 10-Q (filed 2018-05-04) ↗ |
Cite this data
StockData. (2026). AbbVie Sevoflurane [legacy through FY20Q1] ($M), quarterly Q1 2017–Q1 2020 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/sevoflurane-us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.